According to the report, the global immunotherapy market is likely to grow from USD 244.1 Billion in 2025 to USD 564.3 Billion in 2035 at a highest CAGR of 8.7% during the time period. The global immunotherapy market is on track for significant growth due to a variety of factors including the rise in incidence of cancer, the increasing use of personalized treatments, and advancements in the field of targeted immune-based therapies.
During this time span, pharmaceutical and biotechnology companies have developed and commercialized new generations of immunotherapies such as checkpoint inhibitors, CAR-T therapies and bispecific antibodies in order to enhance patient outcomes and additionally expand their use in oncology, autoimmune and rare disease indications. Additionally, to traditional immunotherapy, healthcare providers are utilizing biomarker driven stratification and artificial intelligence (AI) assisted clinical trial analysis to improve treatment effectiveness and safety for patients.
Innovations in outpatient treatment, subcutaneous formulations, and improved combinations of multiple treatment modalities increase the convenience and accessibility to patients. The growing emphasis on real-world evidence and personalized medicine will allow for customized therapeutic approaches that support the widespread adoption and accelerate the clinical impact of new immunotherapy agents among hospitals, research institutions and specialty care centers globally through 2023.
Key Driver, Restraint, and Growth Opportunity Shaping the Global Immunotherapy Market
The primary obstacles facing advanced therapies like CAR-T, which are based on utilizing cells to treat patients (in this case, CAR-T uses T-cells) are high costs, making them very hard for many patients or physician offices to obtain, (CAR-T uses high tech manufacturing processes that are not available everywhere in the world). Additionally, complex designs require special clean rooms and refrigeration (to keep them sterile and alive) and long lead times to process and ship to all over the world (typically 15-30 days).
One of the most exciting new areas of immunotherapy development is the potential emergence of "off-the-shelf" allogeneic therapies like CAR-NK cells which will allow organizations to create large scale cell therapies for multiple patients instead of needing to manufacture each of them and provide better safety profiles (not using patient-derived cells).
Impact of Global Tariff Policies on the Immunotherapy Market Growth and Strategy
Immunotherapy is likely to change significantly due to changes in regulatory frameworks, pricing policies and global healthcare systems that affect how advanced immune-based therapies are developed, approved and brought to market by pharmaceutical companies. Pharmaceutical firms are diversifying their clinical trial networks, biologics manufacturing locations and supply chains across North America, Europe and Asia Pacific to offset regulatory uncertainty, maximize production capacity, and provide uniform access to therapies, such as checkpoint inhibitors and cell-based treatments, throughout the world.
Simultaneously, the rising costs of manufacturing biologics, constructing specialized cell therapy manufacturing facilities and maintaining complex cold-chain transportation systems is causing manufacturers to reassess their pricing strategy and operational models. This pressure is particularly true for personalized therapies, like CAR-T and T-cell receptor-based therapies, which require advanced manufacturing processes and stringent quality control measures.
In response, many governments are enhancing their domestic biopharmaceutical manufacturing capabilities through investment in national innovation and biotechnology programs. The United States, through the Cancer Moonshot program; China, through its biotechnology development strategy; and India, with its National Biopharma Mission, are all focused on advancing immunotherapy research; building out clinical infrastructures.
And further, increasing local manufacturing capabilities, thereby helping to create a more resilient supply chain and supporting long-term growth of the global immunotherapy ecosystem.
Expansion of Global Immunotherapy Market
Technological Innovation, Expanded Clinical Applications, and Strategic R&D Investments Driving the Global Immunotherapy Market Expansion
Regional Analysis of Global Immunotherapy Market
Prominent players operating in global immunotherapy market include prominent companies such as AbbVie Inc., Adaptimmune Therapeutics plc, Agenus Inc., Amgen Inc., AstraZeneca plc, BioNTech SE, Bluebird Bio, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Immunocore Holdings plc, Johnson & Johnson, Merck & Co., Inc., Moderna, Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, along with several other key players.
The global immunotherapy market has been segmented as follows:
Global Immunotherapy Market Analysis, by Therapy Type
Global Immunotherapy Market Analysis, by Mechanism of Action
Global Immunotherapy Market Analysis, by Indication
Global Immunotherapy Market Analysis, by Therapy Area
Global Immunotherapy Market Analysis, by Drug Class
Global Immunotherapy Market Analysis, by Route of Administration
Global Immunotherapy Market Analysis, by Patient Type
Global Immunotherapy Market Analysis, by End User
Global Immunotherapy Market Analysis, by Distribution Channel
Global Immunotherapy Market Analysis, by Region
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact Us
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
info@marketgenics.co
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
sales@marketgenics.co
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation